This inventor holds 1 USPTO granted patent. Top assignees: St. Jude Children's Research Hospital, University of Massachusetts. Active years: 2000.
Company Filing History:
1 out of 281 
1 out of 1,625 
Years Active: 2000
Title: Cong-Mei Zeng: Innovator in Nuclear Matrix Targeting Peptides
Introduction
Cong-Mei Zeng is a notable inventor based in Topsfield, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of nuclear matrix targeting peptides. His work has the potential to enhance the delivery of therapeutic and diagnostic agents to the nuclear matrix of cells.
Latest Patents
Cong-Mei Zeng holds a patent for an "Isolated Nuclear Matrix Targeting Peptide." This patent describes nuclear matrix targeting peptides (NMTPs) that are capable of delivering a variety of therapeutic and diagnostic agents, such as transcription regulatory factors, to the nuclear matrix of a cell. This innovation represents a significant advancement in targeted drug delivery systems.
Career Highlights
Throughout his career, Cong-Mei Zeng has worked with prestigious institutions, including St. Jude Children's Research Hospital and the University of Massachusetts. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Some of his notable coworkers include Jeanne B. Lawrence and Andre J. Van Wijnen. Their collaborative efforts have furthered the understanding and application of nuclear matrix targeting peptides in therapeutic contexts.
Conclusion
Cong-Mei Zeng's innovative work in the field of nuclear matrix targeting peptides showcases his dedication to advancing biotechnology. His contributions have the potential to significantly impact therapeutic delivery methods in medicine.